HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Nishiya, Anna S ^a,b   De Almeida Neto, Cesar ^a,c   Ferreira, Suzete C ^a,b   Alencar, Cecília S ^b,c   Di Lorenzo Oliveira, Claudia ^d   Levi, José E ^a   Salles, Nanci A ^a   Mendrone Jr , Alfredo ^a   Sabino, Ester C ^b,c  

^a FUNDAÇÃO PRÓ SANGUE HEMOCENTRO DE SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Federal University of São Joãodel Rei   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; PROTEINASE INHIBITOR; SIMEPREVIR; TELAPREVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD DONOR; BRAZIL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; GENETIC VARIABILITY; HEPATITIS C; HUMAN; IMMUNOBLOTTING; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD DONORS; BRAZIL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEASE INHIBITORS; RISK FACTORS; YOUNG ADULT;

EID: 84898884314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086413     Document Type: Article

References (80)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362. (Pubitemid 19117877)
2. Organization WH (2012) Hepatitis C. In: N°164 Fs, editor. pp. available: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August 2013.
3. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29 Suppl 1: 74-81.
4. Donahue JG, Munoz A, Ness PM, Brown DE, Jr., Yawn DH, et al. (1992) The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327: 369-373.
5. Wasley A, Miller JT, Finelli L (2007) Surveillance for acute viral hepatitis - United States, 2005. MMWR Surveill Summ 56: 1-24.
6. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, et al. (2007) Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. Aids 21: 983-991. (Pubitemid 46684329)
7. Tohme RA, Holmberg SD (2010) Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 52: 1497-1505.
8. Lopes CL, Teles SA, Espirito-Santo MP, Lampe E, Rodrigues FP, et al. (2009) Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil. Rev Saude Publica 43 Suppl 1: 43-50.
9. Oliveira ML, Hacker MA, Oliveira SA, Telles PR, O KM, et al. (2006) "The first shot": the context of first injection of illicit drugs, ongoing injecting practices, and hepatitis C infection in Rio de Janeiro, Brazil. Cad Saude Publica 22: 861-870. (Pubitemid 43657130)
10. Focaccia R, da Conceicao OJ, Sette H, Jr., Sabino E, Bassit L, et al. (1998) Estimated Prevalence of Viral Hepatitis in the General Population of the Municipality of Sao Paulo, Measured by a Serologic Survey of a Stratified, Randomized and Residence-Based Population. Braz J Infect Dis 2: 269-284.
11. Zarife MA, Silva LK, Silva MB, Lopes GB, Barreto ML, et al. (2006) Prevalence of hepatitis C virus infection in north-eastern Brazil: a population-based study. Trans R Soc Trop Med Hyg 100: 663-668.
12. Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, et al. (2013) Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis 13: 60.
13. Salles NA, Sabino EC, Barreto CC, Barreto AM, Otani MM, et al. (2003) [The discarding of blood units and the prevalence of infectious diseases in donors at the Pro-Blood Foundation/Blood Center of Sao Paulo, Sao Paulo, Brazil]. Rev Panam Salud Publica 13: 111-116.
14. Nascimento MC, Mayaud P, Sabino EC, Torres KL, Franceschi S (2008) Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. J Med Virol 80: 53-57. (Pubitemid 350220088)
15. Rosini N, Mousse D, Spada C, Treitinger A (2003) Seroprevalence of HbsAg, Anti-HBc and anti-HCV in Southern Brazil, 1999-2001. Braz J Infect Dis 7: 262-267.
16. Torres KL, Malheiro A, Tateno A, de-Lima TA, Viana-Maia LP, et al. (2009) Hepatitis C virus in blood donors, Brazil. Emerg Infect Dis 15: 676-678.
17. Brandao AB, Fuchs SC (2002) Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study. BMC Gastroenterol 2: 18.
18. Valente VB, Covas DT, Passos AD (2005) [Hepatitis B and C serologic markers in blood donors of the Ribeirao Preto Blood Center]. Rev Soc Bras Med Trop 38: 488-492.
19. de Almeida-Neto C, Sabino EC, Liu J, Blatyta PF, Mendrone-Junior A, et al. (2013) Prevalence of serologic markers for hepatitis B and C viruses in Brazilian blood donors and incidence and residual risk of transfusion transmission of hepatitis C virus. Transfusion 53: 827-834.
20. Simmonds P, Mellor J, Sakuldamrongpanich T, Nuchaprayoon C, Tanprasert S, et al. (1996) Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J Gen Virol 77 (Pt 12): 3013-3024.
21. Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85: 3173-3188.
22. Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M (2012) An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 32: 339-345.
23. Dienstag JL, McHutchison JG (2006) American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130: 231-264; quiz 214-237.
24. NIH (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36: S3-20.
25. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, et al. (1993) Sequence variability in the 59 non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 74 (Pt 4): 661-668. (Pubitemid 23113369)
26. WHO (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6: 35-47.
27. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
28. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965. (Pubitemid 32913521)
29. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM (2004) Structural biology of hepatitis C virus. Hepatology 39: 5-19. (Pubitemid 38461460)
30. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
31. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
32. Jensen DM (2011) A new era of hepatitis C therapy begins. N Engl J Med 364: 1272-1274.
33. Brasil. Ministério da Saúde. Secretaria de Ciência TeIE (2012) Torna pública a decisão de incorporar os inibidores de protease Telaprevir e Boceprevir para tratamento da hepatite crônica C no Sistema Único de Saúde (SUS). In: PORTARIA N° 20 DDJD, editor. pp. available:http://bvsms.saude.gov.br/bvs/saudelegis/sctie/2012/prt0020-2025- 2007-2012.html Acessed may 2013.
34. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, et al. (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132: 1767-1777. (Pubitemid 46677938)
35. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, et al. (2007) SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132: 1270-1278. (Pubitemid 46627577)
36. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, et al. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207-1217.
37. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al. (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-2428.
38. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, et al. (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014-1024.
39. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, et al. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360: 1827-1838.
40. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, et al. (2012) Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 7: e34372.
41. Zeminian LB, Padovani JL, Corvino SM, Silva GF, Pardini MI, et al. (2013) Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors. Mem Inst Oswaldo Cruz 108: 13-17.
42. Hoffmann L, Ramos JA, Souza EV, Araujo Ramos AL, Villela-Nogueira CA, et al. (2013) Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Virol J 10: 57.
43. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, et al. (2012) Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 54: 352-354.
44. Besse B, Coste-Burel M, Bourgeois N, Feray C, Imbert-Marcille BM, et al. (2012) Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. J Virol Methods 185: 94-100.
45. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, et al. (2012) Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 9: 245.
46. Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, et al. (2012) Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 67: 984-987.
47. Peres-da-Silva A, Almeida AJ, Lampe E (2012) Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with directacting antiviral drugs. Mem Inst Oswaldo Cruz 107: 254-261.
48. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, et al. (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48: 1769-1778.
49. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, et al. (2008) Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 198: 800-807.
50. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, et al. (2013) Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87: 1544-1553.
51. Enomoto N, Takada A, Nakao T, Date T (1990) There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun 170: 1021-1025. (Pubitemid 20273369)
52. Calado RA, Rocha MR, Parreira R, Piedade J, Venenno T, et al. (2011) Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. J Med Virol 83: 608-615.
53. Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
54. Felsenstein J (1989) PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics 5: 164-166.
55. Curry S, Qiu P, Tong X (2008) Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods 153: 156-162.
56. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, et al. (2009) Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50: 1709-1718.
57. Welsch C, Domingues FS, Susser S, Antes I, Hartmann C, et al. (2008) Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol 9: R16.
58. Halfon P, Locarnini S (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192-206.
59. Pawlotsky JM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53: 1742-1751.
60. Shindo H, Maekawa S, Komase K, Sueki R, Miura M, et al. (2011) Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol Int.
61. Vermehren J, Susser S, Lange CM, Forestier N, Karey U, et al. (2012) Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J Viral Hepat 19: 120-127.
62. Wyles DL (2012) Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med 20: 139-145.
63. Focaccia R, Baraldo DC, Ferraz ML, Martinelli AL, Carrilho FJ, et al. (2004) Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. Braz J Infect Dis 8: 348-355.
64. Campiotto S, Pinho JR, Carrilho FJ, Da Silva LC, Souto FJ, et al. (2005) Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 38: 41-49. (Pubitemid 40277937)
65. Romano CM, de Carvalho-Mello IM, Jamal LF, de Melo FL, Iamarino A, et al. (2010) Social networks shape the transmission dynamics of hepatitis C virus. PLoS One 5: e11170.
66. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, et al. (2008) Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 198: 1337-1344.
67. Berger A, von Depka Prondzinski M, Doerr HW, Rabenau H, Weber B (1996) Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol 48: 339-343. (Pubitemid 26132811)
68. Rong X, Lu L, Wang J, Xiong H, Huang J, et al. (2012) Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains. PLoS One 7: e52467.
69. Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13: 34-41.
70. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, et al. (2013) Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 158: 235-245.
71. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
72. Oliveira ML, Bastos FI, Sabino RR, Paetzold U, Schreier E, et al. (1999) Distribution of HCV genotypes among different exposure categories in Brazil. Braz J Med Biol Res 32: 279-282. (Pubitemid 129538884)
73. Nakano T, Lu L, Liu P, Pybus OG (2004) Viral gene sequences reveal the variable history of hepatitis C virus infection among countries. J Infect Dis 190: 1098-1108. (Pubitemid 39186797)
74. Oliveira Mde L, Bastos FI, Telles PR, Hacker Mde A, Oliveira SA, et al. (2009) Epidemiological and genetic analyses of Hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil. J Clin Virol 44: 200-206.
75. Vigani AG, Pavan MH, Tozzo R, Goncales ES, Feltrin A, et al. (2008) Comparative study of patients with chronic hepatitis C virus infection due to genotypes 1 and 3 referred for treatment in southeast Brazil. BMC Infect Dis 8: 164.
76. Lampe E, Espirito-Santo MP, Martins RM, Bello G (2010) Epidemic history of Hepatitis C virus in Brazil. Infect Genet Evol 10: 886-895.
77. Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, et al. (2011) Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis 11: 208.
78. Schroter M, Zollner B, Schafer P, Reimer A, Muller M, et al. (2002) Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 40: 1866-1868. (Pubitemid 34493178)
79. Peres-da-Silva A, de Almeida AJ, Lampe E (2010) Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol 155: 807-811.
80. Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462.